Radiation treatment software developer CMS reported that it has been selected to provide proton-beam therapy applications for two new clients and that it is applying for U.S. Food and Drug Administration 510(k) clearance to distribute its intensity-modulated radiation therapy (IMRT) planning system, Monaco, in the United States.
The St. Louis-based CMS said it has been selected by ProCure Treatment Centers to supply proton therapy planning software for its first proton therapy center in Oklahoma City, Okla. ProCure previously reported it had selected IBA to supply the proton therapy equipment for the new center, named the Oklahoma ProCure Treatment Center, which represents first private practice proton center in the U.S.
CMS said it will supply a proton and conventional radiotherapy software planning system that includes eight XiO treatment planning workstations with proton and IMRT planning capabilities.
In related news, the company announced the signing of a collaboration agreement to provide treatment planning support for a single-room proton beam radiotherapy system being developed by Still River Systems of Littleton, Mass.
Pursuant to the agreement, CMS and Still River Systems will work together to ensure that CMS’s XiO treatment planning system interfaces with and supports the specific planning requirements of Still River Systems’ Clinatron 250 proton treatment system, currently in development.
CMS also said that it has completed internal and external validation testing for its new Monaco IMRT planning system and will file for 510(k) clearance for the application with the FDA. The software has already obtained the CE mark and the first customer installations in Europe are scheduled for this summer, according to CMS.